Citations 2
Efficacy of Total‐Body Irradiation‐based Intensified Myeloablative Regimens for Acute Leukemia—An International Collaborative Study
Arai, Yasuyuki , Brazauskas, Ruta , He, Naya, Al‐Homsi, A. Samer, Yanada, Masamitsu , Steinberg, Amir , Hong, Sanghee , Bashey, Asad, Frangoul, Haydar , Verdonck, Leo F. , Aljurf, Mahmoud , Dias, Ajoy , Wirk, Baldeep , Freytes, César O. , Zeidan, Amer M., Lehmann, Leslie , Rangarajan, Hemalatha G. , Hashmi, Shahrukh K. , Yano, Shingo , Ozawa, Yukiyasu , Doki, Noriko, Kanda, Yoshinobu , Fukuda, Takahiro , Katayama, Yuta, Tanaka, Junji, Okamoto, Shinichiro , Saber, Wael , Yanada, Masamitsu , Kanda, Junya , Badawy, Sherif M , Sharma, Akshay , Abid, Muhammad Bilal , Wirk, Baldeep , Hashmi, Shahrukh, Kanda, Yoshinobu , Ichinohe, Tatsuo , Teshima, Takanori , Okamoto, Shinichiro , Atsuta, Yoshiko , Arai, Yasuyuki , Brazauskas, Ruta , Chhabra, Saurabh , Battiwalla, Minoo , Díaz, Miguel Ángel , Badawy, Sherif M. , Lazarus, Hillard M. , Yared, Jean A. , Hashem, Hasan , Sharma, Akshay , Abid, Muhammad Bilal , Zeidan, Amer M. , Gergis, Usama , Beitinjaneh, Amer , Askar, Medhat , Pu, Jeffrey J , Wood, William A. , Kako, Shinichi , Doki, Noriko , Katayama, Yuta
eJHaem | May 28, 2025 | Volume: 6 | Issue: 3 | Pages: No page available
ABSTRACTBackgroundIn this study, we compared outcomes of intensified myeloablative conditioning regimens using large registry data from Japan (Japanese Society for Transplantation and Cellular Therapy) and the United States (Center for International Blood and Marrow Transplant Research).MethodsAdult patients who underwent their first myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia in remission between 2010 and 2018 using conditioning regimens of cyclophosphamide plus total‐body irradiation (CY/TBI), CY/TBI+cytarabine (AraC), or CY/TBI+etoposide (VP16) were included.ResultsThe acute myeloid leukemia (AML) cohort (N = 480, 38.8%) indicated that overall survival (OS) was poorer in CY/TBI+AraC (hazard ratio [HR] 1.46, p < 0.001) and CY/TBI+VP16 (HR 1.39, p = 0.059) compared to CY/TBI. Relapse was not suppressed, while treatment‐related mortality (TRM) was significantly higher (HR 1.78 and 1.74, p < 0.001 and 0.018, respectively). In the acute lymphoblastic leukemia (ALL) cohort (N = 3901, 61.2%), OS was comparable among these regimens. With intensified regimens, relapse was significantly suppressed in CY/TBI+VP16 (HR 0.74, p = 0.005), while TRM was higher (HR 1.21, p = 0.077). No interactions were observed regarding the country.ConclusionIn AML adding AraC and VP16 to CY/TBI had an adverse effect on OS. Conversely, in ALL, adding VP16 or AraC to CY/TBI did not affect survival, but the addition of VP16 reduced the risk of relapse.Clinical Trial RegistrationThe authors have confirmed clinical trial registration is not needed for this submission.
A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
Tamari, Roni , McLornan, Donal P. , Ahn, Kwang Woo , Estrada‐Merly, Noel, Hernández‐Boluda, Juan Carlos , Giralt, Sergio , Palmer, Jeanne , DeFilipp, Zachariah , Marks, David I. , Poel, Marjolein van der , Verdonck, Leo F. , Gupta, Vikas , Ali, Haris , Litzow, Mark R. , Bashey, Asad, Hashmi, Shahrukh K. , Bredeson, Christopher , Rizzieri, David A. , Abid, Muhammad Bilal , Ganguly, Siddhartha , Wirk, Baldeep , Aljurf, Mahmoud , Kindwall‐Keller, Tamila L. , Kharfan‐Dabaja, Mohamed A. , Hildebrandt, Gerhard , Pawarode, Attaphol , Solh, Melhem , Nathan, Sunita , Seo, Sachiko , Scott, Bart L. , Nakamura, Ryotaro , Yakoub‐Agha, Ibrahim , Saber, Wael , DeFilipp, Zachariah , Gupta, Vikas , Ali, Haris , Litzow, Mark R. , Hashmi, Shahrukh K , Pu, Jeffrey J , Bacher, Ulrike , Jain, Tania , Cutler, Corey S. , Kharfan-Dabaja, Mohamed A , Yared, Jean A , Nishihori, Taiga , Seo, Sachiko , Scott, Bart , Nakamura, Ryotaro , Czerw, Tomasz , Yakoub-Agha, Ibrahim , Hernández-Boluda, Juan Carlos , McLornan, Donal , Abid, Muhammad Bilal , Giralt, Sergio , Gale, Robert Peter , Battiwalla, Minoo , Díaz, Miguel Ángel , Lazarus, Hillard M. , Gergis, Usama , Liesveld, Jane L. , Beitinjaneh, Amer , Savani, Bipin N. , Agrawal, Vaibhav , Jain, Tania , Yared, Jean A. , Grunwald, Michael R. , Nishihori, Taiga , Oran, Betül
Blood Advances | May 3, 2023 | Volume: 7 | Issue: 15 | Pages: 3993-4002
10.1182/bloodadvances.2023009886
AbstractTo develop a prognostic model for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) for myelofibrosis (MF), we examined the data of 623 patients undergoing allo-HCT between 2000 and 2016 in the United States (the Center for International Blood and Marrow Transplant Research [CIBMTR] cohort). A Cox multivariable model was used to identify factors prognostic of mortality. A weighted score using these factors was assigned to patients who received transplantation in Europe (the European Bone Marrow Transplant [EBMT] cohort; n = 623). Patient age >50 years (hazard ratio [HR], 1.39; 95% confidence interval [CI], 0.98-1.96), and HLA-matched unrelated donor (HR, 1.29; 95% CI, 0.98-1.7) were associated with an increased hazard of death and were assigned 1 point. Hemoglobin levels <100 g/L at time of transplantation (HR, 1.63; 95% CI, 1.2-2.19) and a mismatched unrelated donor (HR, 1.78; 95% CI, 1.25-2.52) were assigned 2 points. The 3-year overall survival (OS) in patients with a low (1-2 points), intermediate (3-4 points), and high score (5 points) were 69% (95% CI, 61-76), 51% (95% CI, 46-56.4), and 34% (95% CI, 21-49), respectively (P < .001). Increasing score was predictive of increased transplant-related mortality (TRM; P = .0017) but not of relapse (P = .12). The derived score was predictive of OS (P < .001) and TRM (P = .002) but not of relapse (P = .17) in the EBMT cohort as well. The proposed system was prognostic of survival in 2 large cohorts, CIBMTR and EBMT, and can easily be applied by clinicians consulting patients with MF about the transplantation outcomes.